Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2002 7
2003 7
2004 11
2005 14
2006 11
2007 14
2008 19
2009 11
2010 12
2011 23
2012 20
2013 15
2014 19
2015 28
2016 25
2017 23
2018 22
2019 22
2020 21
2021 15
2022 10
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Results by year

Filters applied: . Clear all
Page 1
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team; Quigley DA, Feng FY, Chi KN, Wyatt AW. Herberts C, et al. Among authors: gleave me. Nature. 2022 Aug;608(7921):199-208. doi: 10.1038/s41586-022-04975-9. Epub 2022 Jul 20. Nature. 2022. PMID: 35859180
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. He Y, et al. Among authors: gleave me. Nat Commun. 2021 Mar 9;12(1):1521. doi: 10.1038/s41467-021-21860-7. Nat Commun. 2021. PMID: 33750801 Free PMC article.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: gleave me. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression.
Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, Chan N, Ung L, Altıntaş UB, Bui JM, Wang Y, Fazli L, Oo HZ, Rennie PS, Lack NA, Cherkasov A, Gleave ME, Gsponer J, Lallous N. Zhang F, et al. Among authors: gleave me. Nucleic Acids Res. 2023 Jan 11;51(1):99-116. doi: 10.1093/nar/gkac1158. Nucleic Acids Res. 2023. PMID: 36535377 Free PMC article.
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Beltran H, et al. Among authors: gleave me. Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130. Cancer Discov. 2011. PMID: 22389870 Free PMC article.
Towards precision oncology in advanced prostate cancer.
Ku SY, Gleave ME, Beltran H. Ku SY, et al. Among authors: gleave me. Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7. Nat Rev Urol. 2019. PMID: 31591549 Free PMC article. Review.
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: gleave me. J Urol. 2020 Apr;203(4):733. doi: 10.1097/JU.0000000000000621.02. Epub 2020 Jan 17. J Urol. 2020. PMID: 31951502 No abstract available.
PARP inhibition in castration-resistant prostate cancer.
Nappi L, Gleave ME. Nappi L, et al. Among authors: gleave me. Future Oncol. 2016 Mar;12(5):577-80. doi: 10.2217/fon.16.1. Epub 2016 Jan 21. Future Oncol. 2016. PMID: 26792387 Free article. No abstract available.
Aggressive variants of castration-resistant prostate cancer.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Beltran H, et al. Among authors: gleave me. Clin Cancer Res. 2014 Jun 1;20(11):2846-50. doi: 10.1158/1078-0432.CCR-13-3309. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727321 Free PMC article. Review.
Androgens and prostate cancer.
So AI, Hurtado-Coll A, Gleave ME. So AI, et al. Among authors: gleave me. World J Urol. 2003 Nov;21(5):325-37. doi: 10.1007/s00345-003-0373-9. Epub 2003 Oct 29. World J Urol. 2003. PMID: 14586548 Review.
306 results